Related references
Note: Only part of the references are listed.A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy
Leola Chow et al.
BLOOD (2010)
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
James B. Bussel et al.
BLOOD (2009)
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Ethan M. Shevach
IMMUNITY (2009)
Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis
Terry Gernsheimer
ONCOLOGIST (2009)
Are CD4(+)CD25(-)Foxp3(+) cells in untreated new-onset lupus patients regulatory T cells?
Hua-xia Yang et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
Roberto Stasi et al.
BLOOD (2008)
Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura
Jin Yu et al.
BLOOD (2008)
Refractory immune thrombocytopenic purpura: current strategies for investigation and management
Bethan Psaila et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:: a double-blind randomised controlled trial
David J. Kuter et al.
LANCET (2008)
Angiogenesis is regulated by a novel mechanism:: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released
Joseph E. Italiano et al.
BLOOD (2008)
'Yin-Yang' functions of transforming growth factor-β and T regulatory cells in immune regulation
Yisong Y. Wan et al.
IMMUNOLOGICAL REVIEWS (2007)
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Correction of th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura
Chengshan Guo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2007)
Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function
Aharon Kessel et al.
JOURNAL OF IMMUNOLOGY (2007)
Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome
Yun Ling et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Role of regulatory T cells and FOXP3 in human diseases
Rosa Bacchetta et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production
Sarah E. Allan et al.
INTERNATIONAL IMMUNOLOGY (2007)
Reduced Cd4(+)Cd25(+) T cells in patients with idiopathic thrombocytopenic purpura
Miho Sakakura et al.
THROMBOSIS RESEARCH (2007)
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Biologically active CD40 ligand is elevated in sickle cell anemia - Potential role for platelet-mediated inflammation
Sheritha P. Lee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Mechanisms of suppression by suppressor T cells
H von Boehmer
NATURE IMMUNOLOGY (2005)
Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self
S Sakaguchi
NATURE IMMUNOLOGY (2005)
Cutting edge:: TGF-β signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+ CD25+ T cells
S Huber et al.
JOURNAL OF IMMUNOLOGY (2004)
Cutting edge:: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function
AM Thornton et al.
JOURNAL OF IMMUNOLOGY (2004)
High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura
H Ogawara et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Making sense of latent TGFβ activation
JP Annes et al.
JOURNAL OF CELL SCIENCE (2003)
Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura
M Nagahama et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2002)
The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40
V Henn et al.
BLOOD (2001)
Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura
M Kuwana et al.
BLOOD (2001)
A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura
PO Andersson et al.
ANNALS OF HEMATOLOGY (2000)
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts
YC Cohen et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
